Elezanumab Granted Orphan Drug, Fast Track Designations for Spinal Cord Injury
Elezanumab is a monoclonal antibody of the human IgG1 isotype that works by binding selectively to repulsive guidance molecule A.
Musculoskeletal Pain
MPR Weekly Dose Podcast Episode 50
We cover AstraZeneca’s decision to pause their COVID-19 vaccine trial; New studies indicate benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment gain approval; The first non-hormonal contraceptive is launched; The FDA issues a letter regarding spinal cord stimulators; And we wrap up the latest news on drugs in the pipeline.
FDA: Stimulation Trial Should Be Performed Before Implanting SCS for Pain
The FDA reported that between July 27, 2016 and July 27, 2020, a total of 107,728 medical device reports (MDRs) associated with SCS devices intended for pain were received.
Vitamin C Positively Linked to Skeletal Muscle Mass Measures
Positive links seen for dietary and circulating vitamin C with muscle mass in middle- and older-aged adults.
Orphengesic Forte Now Available for Pain Management
The safety of long-term Orphengesic Forte use has not been established.
MPR Weekly Dose Podcast Episode 48
Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it’s shelf life extended. Also, we recap drug pipeline news from the past week.
ACP/AAFP Publish Guideline on Managing Acute Pain From Musculoskeletal Injuries
This guideline provides recommendations for managing acute pain resulting from non–low back, musculoskeletal injuries in adults.
MPR Weekly Dose Podcast Episode 47
This week we have remdesivir news; A new opioid and spinal muscular atrophy treatments are approved; A sublingual epinephrine treatment; And the latest on Biogen’s investigational Alzheimer disease treatment. Also, we have a brief summary of the other drugs in the pipeline from the past week.
Do Opioids Have a Role in the Management of Knee and Hip Osteoarthritis?
Researchers assessed pain relief and functional improvement in patients receiving opioids for knee or hip osteoarthritis.
FDA Approves Orphengesic Forte for Pain Management
The FDA has approved the supplemental Abbreviated New Drug Application (sANDA) for Orphengesic Forte.
